

# Enalaprilat (dihydrate)

Catalog No: tcsc2199



## Available Sizes

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

84680-54-6

**Formula:**

$C_{18}H_{28}N_2O_7$

**Pathway:**

Metabolic Enzyme/Protease;Autophagy

**Target:**

Angiotensin-converting Enzyme (ACE);Autophagy

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Alternative Names:**

MK-422

**Observed Molecular Weight:**

384.42


## Product Description

Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 1.94 nM.

Target: ACE

Enalaprilat has high affinity for human endothelial ACE with IC<sub>50</sub> of 1.94 nM in vitro binding assay by displacing a saturating concentration of [125I]351A, a radiolabeled lisinopril analogue from ACE binding sites, and shows bradykinin/angiotensin I selectivity ratio of 1.00 calculated from double displacement experiments [1]. Enalaprilat attenuates the IGF-I induced neonatal rat cardiac fibroblast growth (30% reduction) in a concentration-dependent fashion, with IC<sub>50</sub> of 90 nM [2].

Administration of Enalaprilat induces a significant reduction of MAP at 70 minutes compared with the placebo group during haemorrhagic shock in rats, and results in a 50% reduction of CO, a general tendency of EB extravasation which is significant in the kidney and lungs, and a significant increase in ileal EB extravasation (53%) [3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!